When.com Web Search

  1. Ads

    related to: when will eliquis become generic in usa

Search results

  1. Results From The WOW.Com Content Network
  2. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. [39] [40] Pfizer reported revenue of US$6.747 billion for Eliquis in 2023. [41] Apixaban is one of ten medications covered by price negotiations in the US under the Inflation Reduction Act.

  3. Biden targets diabetes drug Jardiance, blood thinner Eliquis ...

    www.aol.com/finance/biden-targets-diabetes-drug...

    The move is expected to cut costs in a few years for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers.

  4. Ozempic, Trulicity among Medicare's priciest drugs, report finds

    www.aol.com/news/ozempic-trulicity-among-medic...

    USA TODAY and Yahoo may earn commission from links in this article. Pricing and availability subject to change. Ozempic, Trulicity among Medicare's priciest drugs, report finds

  5. Explainer-Why the US is negotiating the price of 10 drugs - AOL

    www.aol.com/news/explainer-why-us-negotiating...

    The U.S. government on Tuesday released a list of 10 prescription medicines that will be subject to the first-ever price negotiations by the Medicare health program that covers Americans aged 65 ...

  6. Generic drug - Wikipedia

    en.wikipedia.org/wiki/Generic_drug

    In most cases, generic products become available after the patent protections afforded to the drug's original developer expire. Once generic drugs enter the market, competition often leads to substantially lower prices for both the original brand-name product and its generic equivalents. In most countries, patents give 20 years of protection.

  7. Discovery and development of direct Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]